You searched for 0 | Page 129 of 143

Case Studies Addressing Human Pharmacokinetic Uncertainty Using a Combination of Pharmacokinetic Simulation and Alternative First-in-human Blog Post

PF-184298 ((S)-2,3-dichloro-N-isobutyl-N-pyrrolidin-3-ylbenzamide) and PF-4776548 ((3-(4-fluoro-2-methoxy-benzyl)-7-hydroxy-8,9-dihydro-3H,7H-pyrrolo[2,3-c][1,7]naphthyridin-6-one)) are novel compounds which were selected to progress to human studies. Discordant human pharmacokinetic predictions arose from pre-clinical in vivo studies in rat and dog,…

ST Analysis of the Fetal Electrocardiogram in Intrapartum Fetal Monitoring: A Meta-analysis Blog Post

The objective of this study was to compare the effects of ST-waveform analysis in combination with cardiotocography with conventional cardiotocography for intrapartum fetal monitoring. We searched MEDLINE, Embase, and PubMed…

Exposure-response Relationship of AMG 386 in Combination with Weekly Paclitaxel in Recurrent Ovarian Cancer and Its Implication for Dose Selection Blog Post

The purpose of this study was to characterize exposure–response relationships of AMG 386 in a phase 2 study in advanced ovarian cancer for the facilitation of dose selection in future…

Pre-clinical Metabolism and Disposition of SB939 (Pracinostat), an Orally Active Histone Deacetylase Inhibitor, and Prediction of Human Pharmacokinetics Blog Post

The preclinical absorption, distribution, metabolism, and excretion (ADME) properties of Pracinostat [(2E)-3-[2-butyl-1-[2-(diethylamino) ethyl]-1H-benzimidazol-5-yl]-N-hydroxyarylamide hydrochloride; SB939], an orally active histone deacetylase inhibitor, were characterized and its human pharmacokinetics (PK) was predicted…

Effect of Microgravity on the Pharmacokinetics of Ibuprofen in Humans Blog Post

The pharmacokinetics of ibuprofen were studied under microgravity (µG) conditions and compared with those at normal gravity (1G) in humans. Six healthy human volunteers were given 600 mg oral dose…

Population Pharmacokinetic-pharmacodynamic-disease Progression Model for Effects of Anakinra in Lewis Rats with Collagen-induced Arthritis Blog Post

A population pharmacokinetic-pharmacodynamic-disease progression (PK/PD/DIS) model was developed to characterize the effects of anakinra in collagen-induced arthritic (CIA) rats and explore the role of interleukin-1ß (IL-1ß) in rheumatoid arthritis. The…

A Dose-response Meta-analysis for Quantifying Relative Efficacy of Biologics in Rheumatoid Arthritis Blog Post

We present a dose-response meta-analysis to quantify relative efficacy of biologic disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis (RA). There is a strong rationale for this analysis because,…

Application of a Systems Approach to the Bottom-up Assessment of Pharmacokinetics in Obese Patients: Expected Variations in Clearance Blog Post

The maintenance dose of a drug is dependent on drug clearance, and thus any biochemical and physiological changes in obesity that affect parameters such as cardiac output, renal function, expression…

The Proton Pump Inhibitor, Omeprazole, but not Lansoprazole or Pantoprazole, is a Metabolism-dependent Inhibitor of CYP2C19: Implications for Coadministration with Clopidogrel Blog Post

As a direct-acting inhibitor of CYP2C19 in vitro, lansoprazole is more potent than omeprazole and other proton pump inhibitors (PPIs), but lansoprazole does not cause clinically significant inhibition of CYP2C19…

Pharmacokinetics of Voriconazole Administered Concomitantly with Fluconazole and Population-based Simulation for Sequential Use Blog Post

In clinical practice, antifungal therapy may be switched from fluconazole to voriconazole; such sequential use poses the potential for drug interaction due to cytochrome P450 2C19 (CYP2C19)-mediated inhibition of voriconazole…

Results For "0"